Scarica l'app Stockscreener
2.11
2.22%
-0.048
Dopo l'orario di chiusura:
2.45
0.34
+16.11%
Precedente Chiudi:
$2.158
Aprire:
$2.4499
Volume 24 ore:
1.12M
Relative Volume:
37.73
Capitalizzazione di mercato:
$3.83M
Reddito:
-
Utile/perdita netta:
$-2.77M
Rapporto P/E:
-0.7973
EPS:
-2.6464
Flusso di cassa netto:
$-2.69M
1 W Prestazione:
-1.86%
1M Prestazione:
-2.31%
6M Prestazione:
-9.83%
1 anno Prestazione:
-49.79%
Intervallo 1D:
$2.11
$2.45
Intervallo di 1 settimana:
$2.11
$2.45
Portata 52W:
$1.725
$7.05
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Nome
Xortx Therapeutics Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare XRTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
2.11 | 3.92M | 0 | -2.77M | -2.69M | -2.6464 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xortx Therapeutics Inc Borsa (XRTX) Ultime notizie
XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media
Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com
12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks
XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan
XORTX Therapeutics Inc. (XRTX) Stock Price, News, Quote & History - Yahoo Finance
XORTX Therapeutics Launches Clinical and Commercial Manufacturing of XORLO™to Support Gout Treatment Program - kalkine.ca
XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan
Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView
EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView
Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Re-Engages Investor Relations Program - markets.businessinsider.com
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks
XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView
XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - Kalkine Media
Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView
Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView
Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView
XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign - TipRanks
$2.5M, three months, 10 campaigns: XORTX (Nasdaq: XRTX) bets big on investor marketing after TSXV delist - Stock Titan
XORTX Therapeutics (XRTX) Advances 2.94% to $2.17 as Traders Eye Move Toward $2.28 ResistanceOverbought Signal Alerts - siam.in
XORTX Therapeutics (TSXV:XRTX) Gains 4.59% as Kidney-Disease Pipeline and Sharper Capital Focus Support Positive Momentum - kalkine.ca
XORTX Announces Termination and Postponement of Investor Relations Program - marketscreener.com
XORTX Therapeutics (XRTX) to leave TSXV, delays $2.5M IR campaign - Stock Titan
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting - TipRanks
XORTX Gets US$2.5M Back as TSX Venture Exchange Delisting Awaits Approval - stocktitan.net
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - valueresearchonline.com
XORTX Therapeutics (TSXV:XRTX) Shares Jump 10.8% in a Volatile Session - kalkine.ca
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet - TipRanks
Going-concern warning at XORTX (XRTX) as losses mount - Stock Titan
XORTX Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XORTX Therapeutics (XRTX) Advances 5.28% as Shares Test Resistance at $2.38Institutional Sentiment - vinanet.vn
XORTX (XRTX) Q1 2024 Earnings: Loss of -$1.24 per Share Misses Consensus by 372.2%Earnings Revision Upgrade - vinanet.vn
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo - The Globe and Mail
XORTX Therapeutics (XRTX) Edges Higher at $2.21 as Shares Hold Mid-Range PositionLong Term Entry Picks - dars.gov.et
Board chair exit at XORTX Therapeutics (NASDAQ: XRTX) detailed - Stock Titan
XORTX Therapeutics (XRTX) Climbs 4.92% as Shares Approach Key Resistance at $2.23Fundamentals - dars.gov.et
XORTX Therapeutics (XRTX) Climbs 4.92% to $2.12 as Speculative Interest BuildsSwing Entry Signals - dars.gov.et
XORTX Therapeutics Inc. Announces Resignation of Anthony Giovinazzo from Director Role - marketscreener.com
XORTX Announces Director Resignation - globenewswire.com
XRTX Q1 2024 Earnings: Larger-Than-Expected Loss Highlights Developmental Stage ChallengesProfitability Analysis - vinanet.vn
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight - TipRanks
XORTX Therapeutics (NASDAQ: XRTX) appoints Depesh Narotam as independent director - Stock Titan
XORTX Appoints New Director - GlobeNewswire
Xortx Therapeutics Inc Azioni (XRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):